271 related articles for article (PubMed ID: 21633975)
1. Alzheimer's disease: β-amyloid plaque formation in human brain.
Seeman P; Seeman N
Synapse; 2011 Dec; 65(12):1289-97. PubMed ID: 21633975
[TBL] [Abstract][Full Text] [Related]
2. [Gamma-secretase inhibitors in Alzheimer's disease therapy].
Katarína S; Jan K; Kamil K; Kamil M
Ceska Slov Farm; 2012 Jun; 61(3):93-100. PubMed ID: 22913824
[TBL] [Abstract][Full Text] [Related]
3. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
[TBL] [Abstract][Full Text] [Related]
4. γ-Secretase component presenilin is important for microglia β-amyloid clearance.
Farfara D; Trudler D; Segev-Amzaleg N; Galron R; Stein R; Frenkel D
Ann Neurol; 2011 Jan; 69(1):170-80. PubMed ID: 21280087
[TBL] [Abstract][Full Text] [Related]
5. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
[TBL] [Abstract][Full Text] [Related]
6. The molecular pathology of Alzheimer's disease.
Harrington CR
Neuroimaging Clin N Am; 2012 Feb; 22(1):11-22, vii. PubMed ID: 22284730
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease: cholesterol a menace?
Mathew A; Yoshida Y; Maekawa T; Kumar DS
Brain Res Bull; 2011 Aug; 86(1-2):1-12. PubMed ID: 21741455
[TBL] [Abstract][Full Text] [Related]
8. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease.
Wang J; Ho L; Qin W; Rocher AB; Seror I; Humala N; Maniar K; Dolios G; Wang R; Hof PR; Pasinetti GM
FASEB J; 2005 Apr; 19(6):659-61. PubMed ID: 15650008
[TBL] [Abstract][Full Text] [Related]
9. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model.
Cho HJ; Son SM; Jin SM; Hong HS; Shin DH; Kim SJ; Huh K; Mook-Jung I
FASEB J; 2009 Aug; 23(8):2639-49. PubMed ID: 19332646
[TBL] [Abstract][Full Text] [Related]
10. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
Meredith SC
Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease.
Amtul Z; Wang L; Westaway D; Rozmahel RF
Neuroscience; 2010 Aug; 169(2):781-6. PubMed ID: 20493928
[TBL] [Abstract][Full Text] [Related]
12. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease.
Ho L; Qin W; Pompl PN; Xiang Z; Wang J; Zhao Z; Peng Y; Cambareri G; Rocher A; Mobbs CV; Hof PR; Pasinetti GM
FASEB J; 2004 May; 18(7):902-4. PubMed ID: 15033922
[TBL] [Abstract][Full Text] [Related]
13. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD
J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173
[TBL] [Abstract][Full Text] [Related]
14. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin.
Haugabook SJ; Le T; Yager D; Zenk B; Healy BM; Eckman EA; Prada C; Younkin L; Murphy P; Pinnix I; Onstead L; Sambamurti K; Golde TE; Dickson D; Younkin SG; Eckman CB
FASEB J; 2001 Jan; 15(1):16-18. PubMed ID: 11099491
[TBL] [Abstract][Full Text] [Related]
15. Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C ε-mediated metalloproteinase 2 and 9 levels in β-amyloid infused Alzheimer's disease rat model.
Zara S; Rapino M; Sozio P; Di Stefano A; Nasuti C; Cataldi A
Brain Res; 2011 Sep; 1412():79-87. PubMed ID: 21820649
[TBL] [Abstract][Full Text] [Related]
16. Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms.
Herring A; Lewejohann L; Panzer AL; Donath A; Kröll O; Sachser N; Paulus W; Keyvani K
Neurobiol Dis; 2011 Jun; 42(3):530-8. PubMed ID: 21406231
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's disease therapeutics: new approaches to an ageing problem.
Small DH; Losic D; Martin LL; Turner BJ; Friedhuber A; Aguilar MI
IUBMB Life; 2004 Apr; 56(4):203-8. PubMed ID: 15230347
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
19. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
20. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.
Phiel CJ; Wilson CA; Lee VM; Klein PS
Nature; 2003 May; 423(6938):435-9. PubMed ID: 12761548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
